SCHEDULE: Great Point Partners Reports 7.66% Stake in Promis Neurosciences

Great Point Partners, LLC, along with Dr. Jeffrey R. Jay, M.D. and Ms. Lillian Nordahl, has reported beneficial ownership of 7.66% of Promis Neurosciences Inc. common shares.

Summary

• Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl have jointly filed a Schedule 13G, indicating their beneficial ownership of 736,881 shares of Promis Neurosciences Inc. common stock.
• This represents 7.66% of the class of securities outstanding.
• The filing is an amendment (Amendment No. 1) and is dated June 30, 2026, with the filing date of August 14, 2026.
• The reporting persons are identified as an investment adviser (IA) and individuals with investment/holding company (HC, IN) classifications.
• The shares reported are held through Biomedical Value Fund, L.P. and Biomedical Offshore Value Fund, Ltd., with Great Point Partners, LLC acting as the investment manager.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily indicating a change in beneficial ownership reporting rather than a significant operational or financial event.

Positives

• Significant stake reported by a known investment entity (Great Point Partners) and its key personnel, suggesting potential confidence or strategic interest in Promis Neurosciences.
• The reporting is conducted under Schedule 13G, which is typically for passive investors, implying no intent to influence or control the issuer's management.

Negatives

• The filing does not provide any new financial performance data or operational updates for Promis Neurosciences, limiting insights into the company's current health.
• The beneficial ownership is subject to a 'Beneficial Ownership Cap' of 9.99%, which restricts the exercise of warrants and thus limits the potential increase in ownership without further action.

Risks

• The 'Beneficial Ownership Cap' of 9.99% on warrant exercise could limit the reporting persons' ability to increase their stake or influence, potentially creating a ceiling on their investment.
• The filing is an amendment, suggesting prior reporting or changes in ownership, the details of which are not fully elaborated in this specific document.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Promis Neurosciences. It solely reports on beneficial ownership.

Management Comments

• Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl have entered into a Joint Filing Agreement to file this statement jointly.
• Great Point, Dr. Jay and Ms. Nordahl disclaim beneficial ownership of the BVF Shares and the BOVF Shares except to the extent of their respective pecuniary interests.

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by Great Point Partners, a known healthcare-focused investment firm, indicates a significant passive stake in Promis Neurosciences. Such filings often precede or coincide with strategic shifts or increased institutional interest in a company within the competitive biotechnology and neuroscience sector.

Stakeholder Impact

• Shareholders: The filing may signal increased institutional interest, potentially influencing market perception and stock price, though the passive nature of the filing suggests no immediate control changes.
• Management of Promis Neurosciences: Awareness of a significant passive stake held by an investment firm.
• Creditors: No direct impact indicated, as the filing is about equity ownership and not debt.

Next Steps

• Continued monitoring of Promis Neurosciences' operational and financial performance.
• Observation of any further filings or disclosures from Great Point Partners regarding their stake.

Key Dates

Keywords

Promis Neurosciences, Great Point Partners, Schedule 13G, Beneficial Ownership, Investment Adviser, Common Shares, Warrants, Biomedical Value Fund